ABBREVIATION
Cerebral palsy (CP) is a group of disorders of movement and posture that cause activity limitation and disability, and are attributed to a nonprogressive disruption in early brain development. 1 CP is the most common motor disability in childhood occurring in 2 to 2.5 infants per 1000 live births. 2 Spasticity and dystonia (hypertonia) are the most common types of movement disorder in CP. 2 In addition to motor impairment, children with CP often have a number of comorbidities, including dysphagia, epilepsy, and cognitive impairment. 2, 3 Current treatments for hypertonia include physiotherapy, casting and splinting, oral medications (e.g. baclofen, benzhexol, levodopa), neurosurgery, and orthopaedic surgery. 3 Intramuscular botulinum toxin type A (BoNT-A) injections decrease hypertonia in the targeted muscle group by inhibiting the release of acetylcholine at the neuromuscular junction and suppressing muscle contraction. 4 BoNT-A has a maximal effect by 4 weeks postinjection and wears off after 3 to 4 months. 5 The Gross Motor Function Classification System (GMFCS) enables classification of children with CP based on their gross motor function ability. 6 In ambulant children (GMFCS levels I, II, and III), BoNT-A has been shown to be effective in improving spastic equinus gait and walking pattern; hand grasp and upper limb function; and independence in self-care. 4, [7] [8] [9] [10] Additionally, the treatment has been shown to be effective in non-ambulant children (GMFCS levels IV and V) for decreasing pain; ease of positioning and dressing; and improving hygiene. [11] [12] [13] [14] Adverse events after BoNT-A administration have been reported with an incidence of 3% to 23% of injection episodes, with the majority being transient and mild. 15, 16 Previously reported adverse events temporally linked with BoNT-A injections include pharyngitis, non-specific pain, respiratory tract infection, vomiting, seizures, and urinary incontinence. 16, 17 Children with severe CP (GMFCS levels IV and V) may be at higher risk of adverse events, 18 with one study reporting adverse events in 5% of injection episodes in this group. pneumonia, generalized weakness, and death. 10, 19 These concerns were heightened after the deaths of four children in 2005 after BoNT-A injections, 20 and a case report describing the deterioration in the respiratory and oromotor functions of a 9-year-old male (in GMFCS level V) with repeat BoNT-A injections. 21 In 2008, the US Food and Drug Administration released a black box warning regarding the potential for systemic spread of BoNT-A leading to respiratory distress and death. 18, 22 In 2011, our centre demonstrated severe adverse events in 2.2% of BoNT-A injections. 16 Another centre reported an incidence of severe adverse events of 4% (all in GMFCS level V) in a 16-month prospective study, which prompted them to discontinue BoNT-A treatment in those children. 23 Higher GMFCS level has been found to be associated with increased unplanned hospital admission for respiratory complications after BoNT-A injections. 19 The 2010 international consensus statement recommends cautious dose selection in patients in GMFCS level V and any patient with dysphagia or breathing problems. 10 Additional information surrounding the frequency of specific adverse events after BoNT-A injections is required to enable clinicians and families to make more informed decisions regarding the intervention and the risks associated with it. The aim of our study was to identify the incidence and type of adverse events after BoNT-A injections in a large cohort of children in all GMFCS levels. We also aimed to investigate whether there is a relationship between the incidence of specific types of adverse events or systemic adverse events and GMFCS level.
METHOD Setting
The study was a review of data collected prospectively from a purpose-built BoNT-A database and the medical records of patients attending the Kids Rehab BoNT-A clinic, an outpatient clinic at The Children's Hospital at Westmead, a large tertiary paediatric hospital in Sydney, Australia.
Participants
All children with a diagnosis of CP who received BoNT-A injections between July 2010 and June 2014 were included. Children with other diagnoses were excluded. Guidelines were used to ensure integrity of diagnosis where there was any ambiguity. Children with booked appointments who were not injected were excluded (Fig. 1) .
Procedures
Children undergoing BoNT-A injections at Kids Rehab first undergo an assessment with a multidisciplinary team, including a paediatric rehabilitation specialist, physiotherapist, and occupational therapist, to establish goals and injection sites. The health status of the child in the month prior and any comorbidities are documented at this time.
BoNT-A injections are performed in the same half-day session using a standard protocol typically involving nitrous oxide conscious sedation and topical anaesthetic cream, with the addition of, or substitution with, oral midazolam in some cases. General anaesthetic was used in a minority of cases. During the study time-frame, Botox (Allergan, Irvine, CA, USA) was used in all cases, diluted to 100U/2mL using 0.9% sodium chloride and injected under ultrasound guidance, with dosage according to the child's weight, size of muscle(s) injected, and previous doses used. Standard practice is for Botox total dose to not exceed 16U/kg (up to a maximum of 400U). Adverse events observed by the injecting team at the time of the procedure were documented.
Follow-up was performed either in person or via telephone by one of the clinical team. In two cases follow-up was carried out by e-mail. At this time, health status and adverse events were recorded. Follow-up was planned to occur approximately 30 days postinjection, corresponding to the time at which maximal effect would be expected.
Data from the pro forma were transferred to and stored on a purpose-built MS Access database.
Assessment appointments n=2510

Injecting episodes n=2219
Episodes with follow-up n=2158 (97.3%) BoNT-A, botulinum toxin type A.
What this paper adds
• Adverse events reported at the time of botulinum toxin A injection occurred in 6% of injection episodes.
• Adverse events were reported at follow-up in 22% of injection episodes.
• Children in Gross Motor Function Classification System (GMFCS) levels IV and V have increased rates of systemic adverse events.
• Children in GMFCS levels IV and V report less local weakness and pain.
Adverse event reporting
Adverse events were recorded on a 'per-injection episode' basis, at two time points: at the time of the procedure (by direct observation of the injector), and at the time of follow-up (by parent or carer report). Systemic adverse events were defined as any report of generalized weakness, lower respiratory tract illnesses, dysphagia, or death. 10 For all adverse events requiring treatment or assessment by a medical professional, further details including date at onset, severity and course, treatment, recovery, and associations were recorded. Medical records were used to clarify any details missing from the database.
Ethics
The study was granted ethical approval by the Sydney Children's Hospitals Network Human Research Ethics Committee, approval number LNR/14/SCHN/330.
Statistical analysis
The number of participants with adverse events, the number of adverse events, and the rate of adverse events per 100 injections was reported overall and for each GMFCS level. The number of adverse events was treated as a count variable and negative binomial regression models were chosen to manage overdispersion. Zero-inflated models were considered but did not offer an advantage over the negative binomial model. There were a number of children who changed GMFCS level during the study and were included as separate entries when this occurred. For this reason, a random-effects negative binomial model was chosen to account for correlation amongst those children who changed GMFCS level. An exposure variable was included using number of injections per child over the course of the study. The GMFCS level was entered into the model as a dummy variable in GMFCS level I as the reference category. To assess the overall contribution of GMFCS the likelihood ratio test was used. Incidence rate ratios (IRRs) and their 95% confidence intervals (CIs) were produced.
It was not possible to model bruising at time of injection as count data as there were never multiple occurrences (only 0 or 1 event per participant). A random-effects logistic regression model was used producing odds ratios (ORs) and their 95% CIs.
All tests were two-tailed and statistical significance level was set at p<0.05. All statistical analysis was performed using Stata version 14.1 (StataCorp, College Station, TX, USA).
RESULTS
In total, 591 children and a total of 2219 BoNT-A injection episodes were included in the study. Figure 1 describes the inclusion pathway for injections to be considered in the final analysis. Participant demographics are detailed in Table I . Fifty-eight (10%) children changed GMFCS level during the study time-frame (all changes by one GMFCS level, typically either children who showed gross motor function at the boundaries of GMFCS levels or changes after classification at an early age). Children had a median of four (interquartile range 2-6; range 1-11) injection episodes during the study time-frame. The mean BoNT-A dose administered was 9.6U/kg (SD 4.6). A small number of children received higher Botox doses than typically used: the maximum dose administered for GMFCS levels I, II, and III was 22.9U/kg and for GMFCS level IV and V, 21.9U/kg (Botox in all cases).
Adverse events at the time of procedure
One or more adverse events occurred at the time of the procedure at a rate of 5.9 per 100 injection episodes. There was no statistical evidence of a relationship between the overall incidence of procedural adverse events and GMFCS level.
Distress (1.8 per 100 injection episodes), pain (1.7 per 100 injection episodes), and nausea and/or vomiting (1.7 per 100 injection episodes) were the most common types of procedural adverse events (Table II) . Compared with children in GMFCS level I, children in GMFCS level III were significantly more likely to show distress during the procedure, and children in GMFCS level V were significantly less likely (Table II) .
Adverse events at follow-up
Follow-up data were obtained from 583 children and 2158 (97%) of injection episodes. Fifty-eight (10%) of these children changed GMFCS level during the study. Followup occurred at a median of 26 days postinjection (interquartile range 21-35d).
One or more adverse events were reported at the time of follow-up at a rate of 22.8 per 100 injection episodes (Table III) . There was no statistical evidence of a relationship between the incidence of follow-up adverse events and GMFCS level.
The most common adverse events reported at follow-up were bruising (4.5 per 100 injection episodes), upper respiratory tract infections (4.4 per 100 injection episodes), local weakness (3.7 per 100 injection episodes), pain (3.0 per 100 injection episodes), and flu-like illnesses (2.9 per 100 injection episodes; Table III ). Compared with those (9) 54 (9) Data are n (%). a GMFCS classification changed for some children during study. GMFCS, Gross Motor Function Classification System. involving children in GMFCS level I, there were significantly lower rates of local weakness after injection episodes involving children in GMFCS level V (IRR 0.16; p=0.001) and significantly lower rates of pain after injection episodes involving children in GMFCS levels IV and V (IRR GMFCS level IV: 0.38; GMFCS level V: 0.04 [p<0.001]) (Table III) .
Systemic adverse events
Adverse events suggesting systemic spread of BoNT-A occurred at a rate of 3.6 per 100 injection episodes. Compared with children in GMFCS level I, there was a significantly increased rate of systemic adverse events in injection episodes involving children in GMFCS levels IV (IRR 3.92) and V (IRR 7.37; p<0.001). Rates of generalized weakness were significantly increased in children in GMFCS level V (IRR 11.99; p=0.015). Rates of worsened dysphagia were significantly increased in children in GMFCS level IV (IRR 5.39; p=0.036) and rates of lower respiratory tract illnesses were significantly increased in injection episodes involving children in GMFCS level V (IRR 12.22; p<0.001; Table III) . One child (aged 11.8y, GMFCS level V) died at home 28 days after BoNT-A; this child received BoNT-A as part of palliative treatment for severe intractable dystonia. The death was expected and the case was not referred to the coroner. A further 17 children died during the study time-frame but at times more remote from BoNT-A injection (median 212d, interquartile range 110-473d).
Medical advice for systemic adverse events was sought after 42 (2%) injection episodes. Eighteen (3%) children were hospitalized in the month after BoNT-A injection, including two with life-threatening illnesses. One child (aged 8.8y, GMFCS level V) was admitted to hospital, including a 5-day intensive care admission for adenoviruspositive lower respiratory tract infection 14 days after BoNT-A. One child (aged 10.3y, GMFCS level IV) was admitted for an unexplained episode of decreased level of consciousness 30 days after BoNT-A in the context of previous episodes without preceding BoNT-A injection.
DISCUSSION
Our results represent the largest study to date examining adverse events after BoNT-A injections in children with Odds ratio (OR) determined using logistic regression. GMFCS, Gross Motor Function Classification System. CP. We report a rate of adverse events at the time of the procedure of 5.9 per 100 injection episodes and adverse events at follow-up of 22.8 per 100 injection episodes. Systemic adverse events were reported at a rate of 3.6 per 100 injection episodes. Our results suggest that children with severe CP (GMFCS levels IV and V) have a significantly increased risk of systemic adverse events compared with children with mild-to-moderate CP (GMFCS levels I, II, and III). The rates of procedural and follow-up adverse events we describe herein are similar to those we have reported previously. 16 Other studies have described a much lower incidence of adverse events. 14, 15, 19 We postulate that these differences may represent differences in the methodologies of the studies. The inclusive and non-causal definition of an adverse event we have applied here and the capture of adverse events using a formalized assessment may have contributed to capturing more (minor) adverse events, which may have been under-reported in retrospective analysis.
The increased rate of systemic adverse events in children in GMFCS levels IV and V we describe is supported by previous reports, which suggest that this group is at an increased risk of adverse events and of unplanned hospital admissions after BoNT-A injection. 15, 19 Similar to previous reports, the majority of systemic adverse events in our study were mild, and there was no clear indication that BoNT-A contributed in the two cases of life-threatening illness or one death during the follow-up period. We feel that our results do not support any changes in our BoNT-A practice in children with severe CP but suggest that clinicians and families carefully consider these risks when deciding on treatment.
The relationship between BoNT-A and adverse events is complex. Children with severe CP have increased rates of comorbidities that may predispose them to complications after BoNT-A injections. 24 A recent randomized controlled trial reported similar rates of moderate-to-severe adverse events in both BoNT-A treatment and placebo arms. 25 What we have described in this study is a temporal association between BoNT-A injections and adverse events. For some adverse events (perhaps many) this relationship may also be causative; for others, they may be related to the comorbidities and poor health associated with severe CP and unrelated to BoNT-A injections.
Children's baseline functional abilities are also likely to influence adverse events reporting. In our study, there was a six-fold increased rate of local weakness and a 25-fold increased rate of pain in injection episodes involving children in GMFCS level I compared with injection episodes 
Bold denotes statistical significance (p<0.05).
a Incident rate ratio (IRR), unless otherwise specified. GMFCS, Gross Motor Function Classification System; CI, confidence interval; LR, likelihood ratio; URTI, upper respiratory tract infection; NA, not applicable; LRTI, lower respiratory tract infection.
involving children in GMFCS level V. We feel these differences are likely to have been influenced by their increased baseline gross motor function and communication abilities. Adverse events occurring post BoNT-A are of varying degrees of importance to clinicians and parents/ guardians. Pain or bruising attributable to the injection procedure, for example, may represent more acceptable risks than the risk of generalized weakness, lower respiratory tract illnesses, or dysphagia. It is therefore important to discuss clinically relevant adverse events when discussing the risks of the intervention with families.
Our study has limitations. No follow-up was available in 3% of the cohort, and the range of follow-up time was variable. A large interval between the injection episode and follow-up is likely to have introduced some recall bias. Relying on parent/guardian reporting of adverse events also introduces the possibility of reporting bias. We feel it is likely that we have captured the more serious adverse events because by their nature systemic adverse events and adverse events that require medical follow-up are less vulnerable to these biases. The use of parent and guardian reports for adverse events may mean that subjective experiences of pain and distress were missed in more severe GMFCS cases, but more intensive monitoring of patient comfort was not feasible in the present study.
CONCLUSION
This is one of the largest clinical studies to date of adverse events after BoNT-A injection episodes in children with CP in all GMFCS levels with follow-up data after injections in 97%. Our results suggest that while adverse events after BoNT-A are common, most are minor and self-limiting. Children in GMFCS levels IV and V have an increased rate of systemic adverse events, making the decision to administer BoNT-A injections in these children complex and requiring consideration of risks compared with benefits. In our department, we have continued to treat children in GMFCS levels IV and V with BoNT-A, consistent with the literature supporting the use of BoNT-A to improve quality of life in these children. 10, 11, 14 Further research is required to clarify the relationship between pre-existing comorbidities in children with CP and the incidence and severity of adverse events after BoNT-A injections.
